A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 319 participants.

Also called NCT05628311

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 319 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05628311
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05628311. Randomized; double masking; primary purpose treatment. Start 2023-01-06 (actual); primary completion 2023-10-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Intervention (Other)
placebo
Intervention (Drug)
IBI362
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05628311
Content hash
e008470e4b0ed0faba38f60e3303682f2887f12a368b9615618cafa80c83166d